Cellular senescence throws new insights into patient classification and pharmacological interventions for clinical management of hepatocellular carcinoma

Figure 3 Immunogenomic landscape of three cellular senescence subtypes across TCGA-LIHC. A: The activity of 50 hallmark pathways in three subtypes; B: Abundance of the tumor microenvironment components, transcript levels of immune checkpoints, and stromal and immune scores across subtypes; C–F: Differences in aneuploidy score, cancer-testicular antigen score, homologous recombination defects, and intratumor heterogeneity between subtypes; G: Difference in TIDE score between subtypes; H–J: Differences in IC₅₀ values of cisplatin, doxorubicin and gemcitabine between subtypes. ^aP < 0.05; ^bP < 0.01; ^cP < 0.001. NS: Not significant; TIDE: Tumor Immune Dysfunction and Exclusion.